Bibliography
- CANCER FACTS AND FIGURES: American Cancer Society, New York, NY (2001).
- BYSTRYN JC, SHAPIRO RL, ORATZ R: Cancer vaccines: clinical applications: partially purified tumour antigen vaccines. In: Biologic Therapy of Cancer. 2nd edn DeVita V, Hellman S, Rosenberg SA (eds), JB Lippincott, Philadelphia, PA (1995):668–679.
- BALCH CM, BUZAID AC, SOONG SJ et al.: Final version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma. Clin. Oncol (2001) 19:3635–3648.
- BALCH CM, HOIUGHTON AN, SOBER AJ, SOONG SJ: Cutaneous Melanoma. 3rd edn, Quality Medical Publishing, Inc., St Louis, MS.
- KIRKWOOD JM, STRAWDERMAN MH, ERNSTOFF MS et al: Interferon alfa-2b adjuvant therapy of high risk resected cutaneous melanoma: the Eastern cooperative Oncology Group trial EST 1684. J. Clin. Oncol (1996) 14:7–17.
- LENS M, DAWES M: Inteferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials Clin. Oncol (2002) 20:1818–1825.
- BYSTRYN JC: Antibody response and tumour growth in syngeneic mice immunized to partially purified B16 melanoma associated antigens J. Immunol (1978) 120:96–101.
- LIVINGSTON PO, CALVES MJ, NATOLI EJ: Approaches to augmenting the immunogenicity of the ganglioside GM2 in mice: purified GM2 is superior to wholecells. J. Immunol (1987) 138:1524–1529.
- BYSTRYN JC, BERNSTEIN P, LIU P, VALENTINE F: Immunophentype of human melanoma cells in different metastases. Cancer Res. (1985) 45:1772–1777.
- REYNOLDS SR, CELIS E, SETTE A et al.: HLA-independent heterogeneity of CD8 + T cell responses to MAGE-3, Melan A/ MART-1, gp100, tyrosinase, MC1R and TRP-2 in vaccine-treated melanoma patients. J. Immunol (1998) 161:6970–6976.
- MORTON DL, BARTH A: Vaccine therapy for malignant melanoma. CA Cancerj Clin. (1996) 46:225–244.
- BERD D, MAGUIRE HC Jr, SCHUCHTER L et al.: Autologous haptenmodified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metasteses. Clin. Oncol (1997) 15:2359–2370.
- PARMIANI G, CASTILLI C, DALERBA P et al.: Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?" NMI Cancer Inst. (2002) 94(11):805–818.
- NESTLE FO, ALIJAGIC S, GILLIET M et al.: Vaccination of melanoma patients with peptide or tumour lysate-pulsed dendritic cells. Nat. Med. (1998) 4:328–332.
- MITCHELL MS: Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin. Oncol (1998) 25:623–635.
- REYNOLDS SR, ORATZ R, SHAPIRO RL et al.: Stimulation of CD8 + T cell responses to MAGE-3 and MELAN A/MART-1 by immunization to a polyvalent melanoma vaccine. Int." Cancer (1997) 72:972–976.
- MILLER K, ABELES G, ORATZ R et al.: Improved survival of melanoma patients with an antibody resonse to immunization to a polyvalent melnaoma vaccine. Cancer (1995) 75(2):495–502.
- TAKAHASHI T, JOHNSON TD, NISHINAKAY et al.: IgM antiganglioside antibodies induced by melanoma cell bvaccine correlate with survival of melanoma patients. J. Invest. Dermatol (1999) 112:205–209.
- LIVINGSTON PO, WONG GYC, ADLURI S et al.: Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. Clin. Oncol (1994) 12:1036–1044.
- BYSTRYN JC, ZELENIUCH-JACQUOTTE A, ORATZ R et al.: Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine. Clin. Cancer Res. (2001) 7:1882–1887.
- SOSMAN JA, UNGER JM, LIU PY et al: Southwest Oncology Group. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumour vaccine: impact of HLA class I antigen expression on outcome.Clin. Oncol (2002) 8:2067–2075.